GLI1, CDK4, and MDM2 Co-Amplification Gastric Plexiform Fibromyxoma: A Case Report and Literature Review

IF 3.1 2区 医学 Q2 GENETICS & HEREDITY Genes, Chromosomes & Cancer Pub Date : 2024-11-13 DOI:10.1002/gcc.70005
Shihui Zhang, Ye Yang, Jianwei Li, Zheng Li, Weihua Li, Susheng Shi
{"title":"GLI1, CDK4, and MDM2 Co-Amplification Gastric Plexiform Fibromyxoma: A Case Report and Literature Review","authors":"Shihui Zhang,&nbsp;Ye Yang,&nbsp;Jianwei Li,&nbsp;Zheng Li,&nbsp;Weihua Li,&nbsp;Susheng Shi","doi":"10.1002/gcc.70005","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Plexiform fibromyxoma (PF) is a rare mesenchymal tumor that primarily occurs in gastric origin with a benign behavior. PF commonly harbors the <i>MALAT1::GLI1</i> fusion gene. Here, we describe a case of a 36-year-old female with a PF. Abdominal computed tomography (CT) showed a 3.3 cm mass in the stomach. She underwent laparoscopic partial gastrectomy. Immunohistochemistry (IHC) of the tumor revealed strongly positive staining for <i>CD34</i>, <i>SDHB</i>, <i>STAT6</i>, <i>MDM2</i>, and <i>CDK4</i>. And the tumor showed <i>TP53</i> mutant expression. Next-generation sequencing (NGS) comprehensive genomic profiling identified <i>GLI1</i>, <i>CDK4</i>, and <i>MDM2</i> co-amplification and <i>TP53</i> mutations. Here, we first report a case of a young woman with a PF harboring co-amplification of <i>GLI1</i>, <i>CDK4</i>, and <i>MDM2</i> genes. The patient underwent complete removal of the tumor without the use of radiotherapy or chemotherapy. No recurrence was observed during the follow-up period of 8 months. This study aims to improve our understanding of PF by analyzing the clinicopathological characteristics of this case, including immunohistochemical (IHC) and genetic examination, and reviewing relevant literature.</p>\n </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"63 11","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes, Chromosomes & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/gcc.70005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Plexiform fibromyxoma (PF) is a rare mesenchymal tumor that primarily occurs in gastric origin with a benign behavior. PF commonly harbors the MALAT1::GLI1 fusion gene. Here, we describe a case of a 36-year-old female with a PF. Abdominal computed tomography (CT) showed a 3.3 cm mass in the stomach. She underwent laparoscopic partial gastrectomy. Immunohistochemistry (IHC) of the tumor revealed strongly positive staining for CD34, SDHB, STAT6, MDM2, and CDK4. And the tumor showed TP53 mutant expression. Next-generation sequencing (NGS) comprehensive genomic profiling identified GLI1, CDK4, and MDM2 co-amplification and TP53 mutations. Here, we first report a case of a young woman with a PF harboring co-amplification of GLI1, CDK4, and MDM2 genes. The patient underwent complete removal of the tumor without the use of radiotherapy or chemotherapy. No recurrence was observed during the follow-up period of 8 months. This study aims to improve our understanding of PF by analyzing the clinicopathological characteristics of this case, including immunohistochemical (IHC) and genetic examination, and reviewing relevant literature.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
GLI1、CDK4 和 MDM2 共同扩增胃丛状纤维瘤:病例报告与文献综述
丛状纤维肌瘤(PF)是一种罕见的间叶肿瘤,主要发生在胃源性良性肿瘤。PF通常携带MALAT1::GLI1融合基因。在此,我们描述了一例患有 PF 的 36 岁女性病例。腹部计算机断层扫描(CT)显示胃部有一个 3.3 厘米的肿块。她接受了腹腔镜胃部分切除术。肿瘤的免疫组化(IHC)显示 CD34、SDHB、STAT6、MDM2 和 CDK4 呈强阳性染色。肿瘤还显示出 TP53 突变表达。下一代测序(NGS)综合基因组图谱发现了 GLI1、CDK4 和 MDM2 共同扩增以及 TP53 突变。在此,我们首次报告了一例携带 GLI1、CDK4 和 MDM2 基因共同扩增的 PF 年轻女性患者。患者在未使用放疗或化疗的情况下接受了肿瘤完全切除术。8 个月的随访期间未发现复发。本研究旨在通过分析该病例的临床病理特征,包括免疫组化(IHC)和基因检查,并回顾相关文献,加深我们对 PF 的理解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Genes, Chromosomes & Cancer
Genes, Chromosomes & Cancer 医学-遗传学
CiteScore
7.00
自引率
8.10%
发文量
94
审稿时长
4-8 weeks
期刊介绍: Genes, Chromosomes & Cancer will offer rapid publication of original full-length research articles, perspectives, reviews and letters to the editors on genetic analysis as related to the study of neoplasia. The main scope of the journal is to communicate new insights into the etiology and/or pathogenesis of neoplasia, as well as molecular and cellular findings of relevance for the management of cancer patients. While preference will be given to research utilizing analytical and functional approaches, descriptive studies and case reports will also be welcomed when they offer insights regarding basic biological mechanisms or the clinical management of neoplastic disorders.
期刊最新文献
Peter Besmer, PhD Obituary (1940–2024) Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets Fibromyxoid aSoft Tissue Tumor With PLAG1 Fusion—The First Case in an Adult Patient An Inflammatory Myofibroblastic Tumor With a Novel ALKV1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors Novel HMGA2::COL14A1 Fusion Identified in Xanthogranulomatous Epithelial Tumor/Keratin-Positive Giant Cell Tumor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1